Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abridged index medicus (2) 2
acute coronary syndromes (2) 2
administration & dosage (2) 2
adverse effects (2) 2
aged (2) 2
anticoagulants (2) 2
aspirin (2) 2
aspirin - administration & dosage (2) 2
aspirin - adverse effects (2) 2
aspirin - therapeutic use (2) 2
cardiovascular disease (2) 2
cardiovascular diseases (2) 2
cardiovascular diseases - mortality (2) 2
cardiovascular diseases - prevention & control (2) 2
chemically induced (2) 2
clinical medicine (2) 2
clinical trials (2) 2
combination (2) 2
coronary vessels (2) 2
disease control (2) 2
disease prevention (2) 2
dose-response relationship (2) 2
dose-response relationship, drug (2) 2
double-blind method (2) 2
drug (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
drug therapy, combination (2) 2
epidemiology (2) 2
evidence-based medicine (2) 2
factor xa inhibitors (2) 2
factor xa inhibitors - administration & dosage (2) 2
factor xa inhibitors - adverse effects (2) 2
factor xa inhibitors - therapeutic use (2) 2
female (2) 2
general & internal medicine (2) 2
health risk assessment (2) 2
heart attacks (2) 2
hemorrhage (2) 2
hemorrhage - chemically induced (2) 2
humans (2) 2
klinisk medicin (2) 2
life sciences & biomedicine (2) 2
male (2) 2
medicine, general & internal (2) 2
morbidity (2) 2
mortality (2) 2
myocardial infarction (2) 2
myocardial infarction - epidemiology (2) 2
myocardial infarction - prevention & control (2) 2
platelet aggregation inhibitors (2) 2
platelet aggregation inhibitors - administration & dosage (2) 2
platelet aggregation inhibitors - adverse effects (2) 2
platelet aggregation inhibitors - therapeutic use (2) 2
prevention & control (2) 2
rivaroxaban (2) 2
rivaroxaban - administration & dosage (2) 2
rivaroxaban - adverse effects (2) 2
rivaroxaban - therapeutic use (2) 2
science & technology (2) 2
stroke (2) 2
stroke - epidemiology (2) 2
stroke - prevention & control (2) 2
therapeutic use (2) 2
thromboembolism (2) 2
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (1) 1
amputation (1) 1
amputation - statistics & numerical data (1) 1
amputation/statistics & numerical data (1) 1
aspirin/administration & dosage (1) 1
blood pressure (1) 1
blood supply (1) 1
cardiac arrhythmia (1) 1
cardiovascular diseases/mortality (1) 1
carotid arteries (1) 1
carotid artery (1) 1
carotid artery diseases (1) 1
carotid artery diseases - complications (1) 1
carotid artery diseases - drug therapy (1) 1
carotid artery diseases - epidemiology (1) 1
carotid artery diseases/complications (1) 1
complications (1) 1
coronary artery (1) 1
coronary artery disease (1) 1
coronary artery disease - drug therapy (1) 1
coronary artery disease - epidemiology (1) 1
etiology (1) 1
factor xa inhibitors/administration & dosage (1) 1
heart diseases (1) 1
hemorrhage/chemically induced (1) 1
incidence (1) 1
life sciences (1) 1
lower extremity (1) 1
lower extremity - blood supply (1) 1
lower extremity - surgery (1) 1
lower extremity/blood supply (1) 1
medical imaging (1) 1
mesh: aged (1) 1
mesh: amputation (1) 1
mesh: aspirin (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
by Anand, Sonia S and Eikelboom, John W and Connolly, Stuart J and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Misselwitz, Frank and Varigos, John D and Chen, Edmond and Branch, Kelley and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and CUNEO, CARLOS and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and ABRANTES, JOSE ANTONIO and MANENTI, EULER and MAIA, LILIA and HERNANDES, MAURO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and BRAILE, MARIA and IZUKAWA, NILO and TANAJURA, LUIZ FERNANDO and SERRANO JUNIOR, CARLOS VICENTE and NASI, LUIZ ANTONIO and TYTUS, RICHARD and PANDEY, SHEKHAR and LONN, EVA and CHA, JAMES and VIZEL, SAUL and BABAPULLE, MOHAN and LAMY, ANDRE and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and LAM, ANDY and AL-QOOFI, FAISAL and PETRELLA, ROBERT and GLANZ, ANTHONY and NOISEUX, NICOLAS and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Evidence-based medicine | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
by Connolly, Stuart J and Dagenais, Gilles and Dyal, Leanne and Lanas, Fernando and O'Donnell, Martin and Dans, Anthony L and Ha, Jong-Won and Parkhomenko, Alexandr N and Lonn, Eva and Lisheng, Liu and Torp-Pedersen, Christian and Widimsky, Petr and Maggioni, Aldo P and Felix, Camilo and Hori, Masatsugu and Cook Bruns, Nancy and Anand, Sonia S and Varigos, John D and Fox, Keith A A and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and GARRIDO, MARCELO and INGARAMO, ADRIAN and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and GUZMAN, LUIS and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ZIMMERMANN, SERGIO LUIZ and RECH, RAFAEL and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and DUTRA, OSCAR and BRAILE, MARIA and IZUKAWA, NILO and NICOLAU, JOSE CARLOS and TANAJURA, LUIZ FERNANDO and MINELLI, CESAR and OLIVEIRA, LIVIA and DE CARVALHO CANTARELLI, MARCELO JOSE and TYTUS, RICHARD and PANDEY, SHEKHAR and CHA, JAMES and BABAPULLE, MOHAN and LAMY, ANDRE and SAUNDERS, KEVIN and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and AL-QOOFI, FAISAL and BROWN, CRAIG and RICCI, JOSEPH A and GLANZ, ANTHONY and NOISEUX, NICOLAS and ... and COMPASS investigators and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Evidence-based medicine | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Drug | drug therapy | chemically induced | prevention & control | Coronary Artery Disease | Clinical Medicine | Myocardial Infarction | Platelet Aggregation Inhibitors | adverse effects | mortality | Dose-Response Relationship | therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.